Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Accured Expenses (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Change in Accured Expenses readings, the most recent being $2.3 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 45.1% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a 2.0% increase, with the full-year FY2025 number at $3.7 million, up 2.0% from a year prior.
  • Change in Accured Expenses hit $2.3 million in Q4 2025 for Xeris Biopharma Holdings, up from $297000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $14.6 million in Q4 2022 to a low of -$13.7 million in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was $1.8 million (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 1234.34% in 2024 and later surged 518.02% in 2025.
  • Xeris Biopharma Holdings' Change in Accured Expenses stood at $7.9 million in 2021, then soared by 85.2% to $14.6 million in 2022, then crashed by 86.67% to $2.0 million in 2023, then surged by 117.88% to $4.3 million in 2024, then tumbled by 45.1% to $2.3 million in 2025.
  • The last three reported values for Change in Accured Expenses were $2.3 million (Q4 2025), $297000.0 (Q3 2025), and $9.7 million (Q2 2025) per Business Quant data.